David R Strayer

Summary

Publications

  1. ncbi Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans
    David R Strayer
    Hemispherx Biopharma, Inc, Philadelphia, PA 19103, USA
    Infect Disord Drug Targets 14:37-43. 2014
  2. pmc A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome
    David R Strayer
    Hemispherx Biopharma, Inc, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 7:e31334. 2012
  3. doi Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies
    David R Strayer
    Department of Clinical Research, Hemispherx Biopharma, Inc, Philadelphia, Pennsylvania 19103, USA
    J Interferon Cytokine Res 32:95-102. 2012
  4. doi Protection from pulmonary tissue damage associated with infection of cynomolgus macaques by highly pathogenic avian influenza virus (H5N1) by low dose natural human IFN-α administered to the buccal mucosa
    David R Strayer
    Hemispherx Biopharma, Inc, Philadelphia, PA 19103, United States
    Antiviral Res 110:175-80. 2014

Detail Information

Publications4

  1. ncbi Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans
    David R Strayer
    Hemispherx Biopharma, Inc, Philadelphia, PA 19103, USA
    Infect Disord Drug Targets 14:37-43. 2014
    ..The most active drugs against SARS/MERS CoV at clinically achievable serum levels were type I interferons and a TLR3 agonist, interferon inducer/activator. ..
  2. pmc A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome
    David R Strayer
    Hemispherx Biopharma, Inc, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 7:e31334. 2012
    ..The objective of the study was to examine the efficacy and safety of a TLR-3 agonist, rintatolimod (Poly I: C(12)U), in patients with debilitating CFS/ME...
  3. doi Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies
    David R Strayer
    Department of Clinical Research, Hemispherx Biopharma, Inc, Philadelphia, Pennsylvania 19103, USA
    J Interferon Cytokine Res 32:95-102. 2012
    ..This result is consistent with serology studies showing that the NABs directed against r-IFNs do not effectively cross-react with n-IFNs...
  4. doi Protection from pulmonary tissue damage associated with infection of cynomolgus macaques by highly pathogenic avian influenza virus (H5N1) by low dose natural human IFN-α administered to the buccal mucosa
    David R Strayer
    Hemispherx Biopharma, Inc, Philadelphia, PA 19103, United States
    Antiviral Res 110:175-80. 2014
    ..Clinical trial data will be necessary to establish its prophylactic human efficacy for highly pathogenic influenza viruses. ..